JP2006519791A - 新規なnphインスリン製剤 - Google Patents
新規なnphインスリン製剤 Download PDFInfo
- Publication number
- JP2006519791A JP2006519791A JP2006504321A JP2006504321A JP2006519791A JP 2006519791 A JP2006519791 A JP 2006519791A JP 2006504321 A JP2006504321 A JP 2006504321A JP 2006504321 A JP2006504321 A JP 2006504321A JP 2006519791 A JP2006519791 A JP 2006519791A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharmaceutical formulation
- aryl
- optionally substituted
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 0 *=C(C=Cc(cc1)ccc1NC(c(cc1)cc(N)c1N)=*)O Chemical compound *=C(C=Cc(cc1)ccc1NC(c(cc1)cc(N)c1N)=*)O 0.000 description 26
- BQCIJWPKDPZNHD-UHFFFAOYSA-N Brc(cc1)cc2c1nn[nH]2 Chemical compound Brc(cc1)cc2c1nn[nH]2 BQCIJWPKDPZNHD-UHFFFAOYSA-N 0.000 description 1
- OBRPCNBOXUKRNG-RMKNXTFCSA-N C/C(/c(cc1)ccc1Br)=C(/C(N1)=O)\SC1=S Chemical compound C/C(/c(cc1)ccc1Br)=C(/C(N1)=O)\SC1=S OBRPCNBOXUKRNG-RMKNXTFCSA-N 0.000 description 1
- LMVGFJXCHDRJRD-LDADJPATSA-N C/[O]=C(\C(C(S1)=S)=C)/C1=C\c(cc1)ccc1OCc1ccccc1 Chemical compound C/[O]=C(\C(C(S1)=S)=C)/C1=C\c(cc1)ccc1OCc1ccccc1 LMVGFJXCHDRJRD-LDADJPATSA-N 0.000 description 1
- KFOJYJFTPAVVJE-MDWZMJQESA-N C=C(C(/C(/S1)=C\c(ccc2ccccc22)c2O)=O)C1=S Chemical compound C=C(C(/C(/S1)=C\c(ccc2ccccc22)c2O)=O)C1=S KFOJYJFTPAVVJE-MDWZMJQESA-N 0.000 description 1
- IRPXUBIEHGBMCF-UHFFFAOYSA-N C=NC(CSC1C=CC(C(NC(C=C2C3)=CC(C4)C24c2c3cccc2)=O)=CC1)NN Chemical compound C=NC(CSC1C=CC(C(NC(C=C2C3)=CC(C4)C24c2c3cccc2)=O)=CC1)NN IRPXUBIEHGBMCF-UHFFFAOYSA-N 0.000 description 1
- DTVYNCCDHCYLEQ-UHFFFAOYSA-O C=NC(CSc(cc1)ccc1C(Nc(c([OH2+])c1)ccc1C(O)=O)=O)=N Chemical compound C=NC(CSc(cc1)ccc1C(Nc(c([OH2+])c1)ccc1C(O)=O)=O)=N DTVYNCCDHCYLEQ-UHFFFAOYSA-O 0.000 description 1
- NXNJVPOWGIKZDE-MOHJPFBDSA-N C=[N]=C(CCCCCCCCCCCOc(cc1)cc2c1cc(/C=C(/C(N1)O)\SC1=O)cc2)O Chemical compound C=[N]=C(CCCCCCCCCCCOc(cc1)cc2c1cc(/C=C(/C(N1)O)\SC1=O)cc2)O NXNJVPOWGIKZDE-MOHJPFBDSA-N 0.000 description 1
- YLVZDYSHCKJRLY-UHFFFAOYSA-N CC(C)(C=CC1C2)C=CC1=CC(O)=C2C(O)=O Chemical compound CC(C)(C=CC1C2)C=CC1=CC(O)=C2C(O)=O YLVZDYSHCKJRLY-UHFFFAOYSA-N 0.000 description 1
- QKMXBEZLGNNTIJ-UHFFFAOYSA-N CC(C)c(cc1)ccc1NCc1ccc(cc(c(C(O)=O)c2)O)c2c1 Chemical compound CC(C)c(cc1)ccc1NCc1ccc(cc(c(C(O)=O)c2)O)c2c1 QKMXBEZLGNNTIJ-UHFFFAOYSA-N 0.000 description 1
- ACYVYTKXKDHHRI-UHFFFAOYSA-O CC(C1)C(CNc2cc(C(/N=N\N)=[NH2+])ccc2)=Cc2c1cccc2 Chemical compound CC(C1)C(CNc2cc(C(/N=N\N)=[NH2+])ccc2)=Cc2c1cccc2 ACYVYTKXKDHHRI-UHFFFAOYSA-O 0.000 description 1
- RTNHXORZZJMORP-ODLFYWEKSA-N CC(C1/C=C(/C(N2)=O)\SC2=O)N(Cc(cc2)ccc2C(OC)=O)c2c1cccc2 Chemical compound CC(C1/C=C(/C(N2)=O)\SC2=O)N(Cc(cc2)ccc2C(OC)=O)c2c1cccc2 RTNHXORZZJMORP-ODLFYWEKSA-N 0.000 description 1
- LRVYIIGPRSJCSZ-UHFFFAOYSA-N CC(c(cc1)ccc1-c1ccc(cc(c(C(O)=O)c2)O)c2c1)=O Chemical compound CC(c(cc1)ccc1-c1ccc(cc(c(C(O)=O)c2)O)c2c1)=O LRVYIIGPRSJCSZ-UHFFFAOYSA-N 0.000 description 1
- UPKKCDRSOZTNGF-UHFFFAOYSA-N CC(c1ccccc1)NC(c(cc1)cc2c1[nH]nn2)=O Chemical compound CC(c1ccccc1)NC(c(cc1)cc2c1[nH]nn2)=O UPKKCDRSOZTNGF-UHFFFAOYSA-N 0.000 description 1
- HEVJNEBNMIPCSH-UHFFFAOYSA-N CC/[I]=C(\c1c(CNc2cc(OCc3nc(cccc4)c4cc3)ccc2)cccc1)/NNC Chemical compound CC/[I]=C(\c1c(CNc2cc(OCc3nc(cccc4)c4cc3)ccc2)cccc1)/NNC HEVJNEBNMIPCSH-UHFFFAOYSA-N 0.000 description 1
- JNXWEOWONRYUBB-UHFFFAOYSA-O CC12N(Cc(cccc3)c3Cl)C=CC1=CC(C(/N=N\N)=[NH2+])=CC2 Chemical compound CC12N(Cc(cccc3)c3Cl)C=CC1=CC(C(/N=N\N)=[NH2+])=CC2 JNXWEOWONRYUBB-UHFFFAOYSA-O 0.000 description 1
- WHBFJAYDECRBLH-UHFFFAOYSA-N CCC1NC(c(cc2)ccc2NCc2cc(OCc3ccccc3)ccc2)=CCC1C Chemical compound CCC1NC(c(cc2)ccc2NCc2cc(OCc3ccccc3)ccc2)=CCC1C WHBFJAYDECRBLH-UHFFFAOYSA-N 0.000 description 1
- UPGTXVAMBOKTAR-PLRJNAJWSA-N CCCCCOC(C(CCCCCOC(C1C=CC=CC11)=CC=C1/C=C(/C(N1)=O)\SC1=O)C(OCC)=O)=O Chemical compound CCCCCOC(C(CCCCCOC(C1C=CC=CC11)=CC=C1/C=C(/C(N1)=O)\SC1=O)C(OCC)=O)=O UPGTXVAMBOKTAR-PLRJNAJWSA-N 0.000 description 1
- PGNRXRLQYMNHTO-VZCXRCSSSA-N CCOC(CCCCOc(cc1)cc(cc2)c1cc2/C(/N)=C(\C[N]#C)/N[NH2+2])=O Chemical compound CCOC(CCCCOc(cc1)cc(cc2)c1cc2/C(/N)=C(\C[N]#C)/N[NH2+2])=O PGNRXRLQYMNHTO-VZCXRCSSSA-N 0.000 description 1
- UNMHZJIWHHEJLR-UHFFFAOYSA-N CC[n]1c2cc(C=C(C(NC(N3)=O)=O)C3=O)ccc2c2c1cccc2 Chemical compound CC[n]1c2cc(C=C(C(NC(N3)=O)=O)C3=O)ccc2c2c1cccc2 UNMHZJIWHHEJLR-UHFFFAOYSA-N 0.000 description 1
- HFXCKEUGBNKYRW-GHXNOFRVSA-N CCc1c(/C=C(/C(N2)=O)\SC2=O)c2ccccc2[nH]1 Chemical compound CCc1c(/C=C(/C(N2)=O)\SC2=O)c2ccccc2[nH]1 HFXCKEUGBNKYRW-GHXNOFRVSA-N 0.000 description 1
- XZOKAKNIIYVJTB-UHFFFAOYSA-N CN(Cc1ccccc1)C(c(cc1)cc(N=N)c1N)=O Chemical compound CN(Cc1ccccc1)C(c(cc1)cc(N=N)c1N)=O XZOKAKNIIYVJTB-UHFFFAOYSA-N 0.000 description 1
- GFZKRRYOLYJIBN-GHXNOFRVSA-N COc(cc1)cc2c1c(Br)c(/C=C(/C(N1)=O)\SC1=O)cc2 Chemical compound COc(cc1)cc2c1c(Br)c(/C=C(/C(N1)=O)\SC1=O)cc2 GFZKRRYOLYJIBN-GHXNOFRVSA-N 0.000 description 1
- ZZQSRFASBWWWCX-UHFFFAOYSA-N COc(cc1)ccc1NS(c(cc1)cc(C(O)=O)c1O)(=O)=O Chemical compound COc(cc1)ccc1NS(c(cc1)cc(C(O)=O)c1O)(=O)=O ZZQSRFASBWWWCX-UHFFFAOYSA-N 0.000 description 1
- ZCHBFHCAGSBARE-UITAMQMPSA-N COc1cc(/C=C(/C(N2)=O)\SC2=O)cc(OC)c1O Chemical compound COc1cc(/C=C(/C(N2)=O)\SC2=O)cc(OC)c1O ZCHBFHCAGSBARE-UITAMQMPSA-N 0.000 description 1
- UEUFRMSWRXFGDP-UHFFFAOYSA-N COc1cc(C[n](c(cccc2)c2c2c3)c2ccc3-c2c[nH]nn2)cc(OC)c1 Chemical compound COc1cc(C[n](c(cccc2)c2c2c3)c2ccc3-c2c[nH]nn2)cc(OC)c1 UEUFRMSWRXFGDP-UHFFFAOYSA-N 0.000 description 1
- WMKAINHELBGWNR-UHFFFAOYSA-O COc1ccc(CNc2cccc(C(/N=N\N)=[NH2+])c2)cc1 Chemical compound COc1ccc(CNc2cccc(C(/N=N\N)=[NH2+])c2)cc1 WMKAINHELBGWNR-UHFFFAOYSA-O 0.000 description 1
- GRUDKHGILUCAMR-XFFZJAGNSA-N C[n]1c2ccccc2cc1/C=C(/C(N1)=O)\SC1=O Chemical compound C[n]1c2ccccc2cc1/C=C(/C(N1)=O)\SC1=O GRUDKHGILUCAMR-XFFZJAGNSA-N 0.000 description 1
- HWKFDBCRZKGNRL-UHFFFAOYSA-O Cc(cc1)cc2c1N[NH2+]N2 Chemical compound Cc(cc1)cc2c1N[NH2+]N2 HWKFDBCRZKGNRL-UHFFFAOYSA-O 0.000 description 1
- ZEGKYQUFOYTKBK-HJWRWDBZSA-N Cc(cc1/C2=C(\C(N3)=O)/SC3=S)ccc1NC2=O Chemical compound Cc(cc1/C2=C(\C(N3)=O)/SC3=S)ccc1NC2=O ZEGKYQUFOYTKBK-HJWRWDBZSA-N 0.000 description 1
- YMMMPMBZXSSZPX-UHFFFAOYSA-N Cc1c(C)c(C[n](c(cccc2)c2c2c3)c2ccc3-c2n[nH]nn2)c(C)c(C)c1 Chemical compound Cc1c(C)c(C[n](c(cccc2)c2c2c3)c2ccc3-c2n[nH]nn2)c(C)c(C)c1 YMMMPMBZXSSZPX-UHFFFAOYSA-N 0.000 description 1
- VTCLGQWQZMARRI-UHFFFAOYSA-N Fc1cccc-2c1C[n]1c(cccc3)c3c3c1c-2cc(-c1n[nH]nn1)c3 Chemical compound Fc1cccc-2c1C[n]1c(cccc3)c3c3c1c-2cc(-c1n[nH]nn1)c3 VTCLGQWQZMARRI-UHFFFAOYSA-N 0.000 description 1
- UMZYRVLHXVTUSE-UHFFFAOYSA-N N/N=N\C(c(cc1)ccc1NCc(cc1)ccc1Br)=N Chemical compound N/N=N\C(c(cc1)ccc1NCc(cc1)ccc1Br)=N UMZYRVLHXVTUSE-UHFFFAOYSA-N 0.000 description 1
- ADVIVMFMYKMOKU-BJMVGYQFSA-O N/N=N\C(c(cc1)ccc1NCc1ccc(/C=C/C(O)=O)cc1)=[NH2+] Chemical compound N/N=N\C(c(cc1)ccc1NCc1ccc(/C=C/C(O)=O)cc1)=[NH2+] ADVIVMFMYKMOKU-BJMVGYQFSA-O 0.000 description 1
- YIWBNXZPGNVRML-UHFFFAOYSA-O N/N=N\C(c1ccc2[nH]ccc2c1)=[NH2+] Chemical compound N/N=N\C(c1ccc2[nH]ccc2c1)=[NH2+] YIWBNXZPGNVRML-UHFFFAOYSA-O 0.000 description 1
- VPSWNCVQPNCJKP-UHFFFAOYSA-O N/N=N\C(c1ccc2[n](Cc(cc(c(F)c3)F)c3F)c3ccccc3c2c1)=[NH2+] Chemical compound N/N=N\C(c1ccc2[n](Cc(cc(c(F)c3)F)c3F)c3ccccc3c2c1)=[NH2+] VPSWNCVQPNCJKP-UHFFFAOYSA-O 0.000 description 1
- DNBYOTLTOFSKJP-UHFFFAOYSA-O N/N=N\C(c1ccc2[n](Cc(ccc(Cl)c3)c3Cl)ccc2c1)=[NH2+] Chemical compound N/N=N\C(c1ccc2[n](Cc(ccc(Cl)c3)c3Cl)ccc2c1)=[NH2+] DNBYOTLTOFSKJP-UHFFFAOYSA-O 0.000 description 1
- NDLWIWPPTHJJNX-UHFFFAOYSA-O N/N=N\C(c1cccc(NCc2ccccc2)c1)=[NH2+] Chemical compound N/N=N\C(c1cccc(NCc2ccccc2)c1)=[NH2+] NDLWIWPPTHJJNX-UHFFFAOYSA-O 0.000 description 1
- JCCNTTPOUVAOJP-YFJSSSIFSA-N N=C/C(/c1cccc(C=O)c1)=C(/C(N1)=O)\SC1=S Chemical compound N=C/C(/c1cccc(C=O)c1)=C(/C(N1)=O)\SC1=S JCCNTTPOUVAOJP-YFJSSSIFSA-N 0.000 description 1
- LPVJTKUJZBBBCP-UHFFFAOYSA-N N=Cc1c(-c2c(cccc3)c3cc3c2cccc3)nn[nH]1 Chemical compound N=Cc1c(-c2c(cccc3)c3cc3c2cccc3)nn[nH]1 LPVJTKUJZBBBCP-UHFFFAOYSA-N 0.000 description 1
- NVONPHQCYVFBJP-UHFFFAOYSA-O NC(c1cc2ccccc2cc1)=NN[NH3+] Chemical compound NC(c1cc2ccccc2cc1)=NN[NH3+] NVONPHQCYVFBJP-UHFFFAOYSA-O 0.000 description 1
- RPUCSMKPHYHGSL-UHFFFAOYSA-N NCc(cc1)cc(cc2C(O)=O)c1cc2O Chemical compound NCc(cc1)cc(cc2C(O)=O)c1cc2O RPUCSMKPHYHGSL-UHFFFAOYSA-N 0.000 description 1
- UOCKKQIWJNNOGC-KRWDZBQOSA-N NN/C(/c1cc(-c2c([C@@H](CCC3=CC=CCC3)C3)cccc2)c3cc1)=N\N Chemical compound NN/C(/c1cc(-c2c([C@@H](CCC3=CC=CCC3)C3)cccc2)c3cc1)=N\N UOCKKQIWJNNOGC-KRWDZBQOSA-N 0.000 description 1
- CJXDQHJOQFCCNF-UHFFFAOYSA-O Nc(cc(cc1)C(Nc(cc2)ccc2C(NCCC(O)=O)=O)=O)c1[NH3+] Chemical compound Nc(cc(cc1)C(Nc(cc2)ccc2C(NCCC(O)=O)=O)=O)c1[NH3+] CJXDQHJOQFCCNF-UHFFFAOYSA-O 0.000 description 1
- ALUBNKDROOYPRX-YWEYNIOJSA-N O=C(/C(/S1)=C/C(C(F)=CCC2)=C2F)NC1=O Chemical compound O=C(/C(/S1)=C/C(C(F)=CCC2)=C2F)NC1=O ALUBNKDROOYPRX-YWEYNIOJSA-N 0.000 description 1
- IGAKPZUHZYZWKU-CLTKARDFSA-N O=C(/C(/S1)=C/c(c(Cl)c(cc2)Cl)c2Cl)NC1=O Chemical compound O=C(/C(/S1)=C/c(c(Cl)c(cc2)Cl)c2Cl)NC1=O IGAKPZUHZYZWKU-CLTKARDFSA-N 0.000 description 1
- FKSQUNCVENBSMC-YWEYNIOJSA-N O=C(/C(/S1)=C/c(c(Cl)ccc2)c2Cl)NC1=O Chemical compound O=C(/C(/S1)=C/c(c(Cl)ccc2)c2Cl)NC1=O FKSQUNCVENBSMC-YWEYNIOJSA-N 0.000 description 1
- CYRHPZRZCQAYLN-YBEGLDIGSA-N O=C(/C(/S1)=C/c2cc(CCCC3)c3c3c2cccc3)NC1=O Chemical compound O=C(/C(/S1)=C/c2cc(CCCC3)c3c3c2cccc3)NC1=O CYRHPZRZCQAYLN-YBEGLDIGSA-N 0.000 description 1
- YXDYUYLHVUQYKV-YVMONPNESA-N O=C(/C(/S1)=C/c2ccccc2C(F)(F)F)NC1=O Chemical compound O=C(/C(/S1)=C/c2ccccc2C(F)(F)F)NC1=O YXDYUYLHVUQYKV-YVMONPNESA-N 0.000 description 1
- HZLRXYSUEXNFEB-XFFZJAGNSA-N O=C(/C(/S1)=C/c2nc3ccccc3cc2)NC1=O Chemical compound O=C(/C(/S1)=C/c2nc3ccccc3cc2)NC1=O HZLRXYSUEXNFEB-XFFZJAGNSA-N 0.000 description 1
- LMEZUNCOXQJPMX-UHFFFAOYSA-N O=C(c(cc1)cc2c1[nH]nn2)NCc1ccccc1 Chemical compound O=C(c(cc1)cc2c1[nH]nn2)NCc1ccccc1 LMEZUNCOXQJPMX-UHFFFAOYSA-N 0.000 description 1
- MIKCKLBZRSSFFG-UHFFFAOYSA-N O=C(c1cc(cccc2)c2cc1)[n](cc1)c(cc2)c1cc2-c1n[nH]nn1 Chemical compound O=C(c1cc(cccc2)c2cc1)[n](cc1)c(cc2)c1cc2-c1n[nH]nn1 MIKCKLBZRSSFFG-UHFFFAOYSA-N 0.000 description 1
- DQIMIIMMLXQQQV-UHFFFAOYSA-N O=C(c1ccccc1)[n](ccc1c2)c1ccc2-c1n[nH]nn1 Chemical compound O=C(c1ccccc1)[n](ccc1c2)c1ccc2-c1n[nH]nn1 DQIMIIMMLXQQQV-UHFFFAOYSA-N 0.000 description 1
- SKRVRVSQHUZLBW-FPLPWBNLSA-N O=C1Nc2ccccc2/C1=C(\C(N1)=O)/SC1=O Chemical compound O=C1Nc2ccccc2/C1=C(\C(N1)=O)/SC1=O SKRVRVSQHUZLBW-FPLPWBNLSA-N 0.000 description 1
- NBOMNTLFRHMDEZ-UHFFFAOYSA-N OC(c(cccc1)c1S)=O Chemical compound OC(c(cccc1)c1S)=O NBOMNTLFRHMDEZ-UHFFFAOYSA-N 0.000 description 1
- RSWPCCADPVMBCT-UHFFFAOYSA-N OC(c1cc(cc(CNCc(cccc2)c2-c2ccccc2)cc2)c2cc1O)=O Chemical compound OC(c1cc(cc(CNCc(cccc2)c2-c2ccccc2)cc2)c2cc1O)=O RSWPCCADPVMBCT-UHFFFAOYSA-N 0.000 description 1
- XZWXQSGFZHRDNB-UHFFFAOYSA-N OC(c1cc2cc(Br)ccc2cc1O)=O Chemical compound OC(c1cc2cc(Br)ccc2cc1O)=O XZWXQSGFZHRDNB-UHFFFAOYSA-N 0.000 description 1
- RTIUWXJUJKDMPG-UHFFFAOYSA-N OC(c1cc2cc(C=O)ccc2cc1O)=O Chemical compound OC(c1cc2cc(C=O)ccc2cc1O)=O RTIUWXJUJKDMPG-UHFFFAOYSA-N 0.000 description 1
- OQNPAAXRGGDLCP-DHDCSXOGSA-O O[N+](c1ccc(COc2ccccc2/C=C(/C(N2)=O)\SC2=O)cc1)=O Chemical compound O[N+](c1ccc(COc2ccccc2/C=C(/C(N2)=O)\SC2=O)cc1)=O OQNPAAXRGGDLCP-DHDCSXOGSA-O 0.000 description 1
- KZZUTIMHWCCPDO-YVMONPNESA-N [O-][NH+](c1cccc(/C=C(/C(N2)=O)\SC2=O)c1)O Chemical compound [O-][NH+](c1cccc(/C=C(/C(N2)=O)\SC2=O)c1)O KZZUTIMHWCCPDO-YVMONPNESA-N 0.000 description 1
- HZAHUPKFCIYWHZ-YVMONPNESA-O [OH2+]c1cccc(/C=C(/C(N2)=O)\NC2=O)c1 Chemical compound [OH2+]c1cccc(/C=C(/C(N2)=O)\NC2=O)c1 HZAHUPKFCIYWHZ-YVMONPNESA-O 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200300383 | 2003-03-13 | ||
US45534103P | 2003-03-17 | 2003-03-17 | |
PCT/DK2004/000160 WO2004080481A1 (en) | 2003-03-13 | 2004-03-12 | Novel nph insulin preparations |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006519791A true JP2006519791A (ja) | 2006-08-31 |
JP2006519791A5 JP2006519791A5 (de) | 2007-04-19 |
Family
ID=32992157
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006504321A Withdrawn JP2006519791A (ja) | 2003-03-13 | 2004-03-12 | 新規なnphインスリン製剤 |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1605967A1 (de) |
JP (1) | JP2006519791A (de) |
WO (1) | WO2004080481A1 (de) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016135778A (ja) * | 2015-01-16 | 2016-07-28 | 大塚製薬株式会社 | シアノトリアゾール化合物の医薬用途 |
JP2016525069A (ja) * | 2013-07-17 | 2016-08-22 | 大塚製薬株式会社 | シアノトリアゾール化合物 |
JP2019510787A (ja) * | 2016-04-05 | 2019-04-18 | イミューン センサー リミテッド ライアビリティ カンパニー | cGASアンタゴニスト化合物 |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2918286T (pt) * | 2004-10-05 | 2020-03-27 | Novo Nordisk As | Formulação farmacêutica |
WO2006104396A1 (en) * | 2005-03-26 | 2006-10-05 | Protemix Corporation Limited | Pre-complexed copper antagonist compositions |
WO2006104400A1 (en) * | 2005-03-26 | 2006-10-05 | Protemix Corporation Limited | Copper antagonist compositions |
JP2009500401A (ja) * | 2005-07-07 | 2009-01-08 | ポステック ファンデーション | 糖吸収調節剤及び薬学的組成物 |
ES2431050T3 (es) | 2005-08-04 | 2013-11-22 | Sirtris Pharmaceuticals, Inc. | Benzotiazoles y tiazolopiridinas como moduladores de la sirtuína |
JP5191155B2 (ja) * | 2006-03-27 | 2013-04-24 | 大塚製薬株式会社 | カルボスチリル化合物からなる医薬 |
CL2008001821A1 (es) | 2007-06-20 | 2009-03-13 | Sirtris Pharmaceuticals Inc | Compuestos derivados de imidazo[2,1-b]-tiazol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de diabetes, sindrome metabolico, resistencia a la insulina, entre otras. |
CN102731429A (zh) * | 2012-07-18 | 2012-10-17 | 西南大学 | 5-芳亚甲基噻唑烷-2,4-二酮及其合成方法和应用 |
MX2017007607A (es) | 2014-12-11 | 2018-05-28 | Harvard College | Inhibidores de necrosis celular y metodos relacionados. |
US11213513B2 (en) | 2017-02-24 | 2022-01-04 | The Regents Of The University Of California | Compositions and methods for promoting hair growth with Mpc1 inhibitors |
IL271443B2 (en) * | 2017-06-30 | 2024-01-01 | Univ California | Preparations and methods for regulating hair growth |
JP7231610B2 (ja) * | 2017-07-28 | 2023-03-01 | ノバルティス アーゲー | インドール誘導体及びその使用 |
CN113929588B (zh) * | 2020-06-29 | 2023-08-15 | 沈阳化工研究院有限公司 | 一种合成4-氨基甲基苯甲酸的方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3060093A (en) * | 1957-07-18 | 1962-10-23 | Nordisk Insulinlab | Slowly acting insulin preparation in crystalline form and method of preparation |
US5830999A (en) * | 1995-01-26 | 1998-11-03 | Regents Of The University Of California | Stabilization of insulin through ligand binding interations |
WO1999021578A1 (en) * | 1997-10-24 | 1999-05-06 | Eli Lilly And Company | Insoluble insulin compositions |
US6531448B1 (en) * | 1997-12-23 | 2003-03-11 | Eli Lilly And Company | Insoluble compositions for controlling blood glucose |
EP1396272A1 (de) * | 1997-12-23 | 2004-03-10 | Eli Lilly & Company | Unlöslische Insulin Zusammensetzungen zur Regelung der Blutglukose |
JP2002529514A (ja) * | 1998-11-18 | 2002-09-10 | ノボ ノルディスク アクティーゼルスカブ | フェノール及びクレゾールを要さない安定なインスリン水性調製物 |
WO2003053460A1 (en) * | 2001-12-19 | 2003-07-03 | Eli Lilly And Company | Crystalline compositions for controlling blood glucose |
-
2004
- 2004-03-12 EP EP04719932A patent/EP1605967A1/de not_active Withdrawn
- 2004-03-12 JP JP2006504321A patent/JP2006519791A/ja not_active Withdrawn
- 2004-03-12 WO PCT/DK2004/000160 patent/WO2004080481A1/en active Application Filing
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016525069A (ja) * | 2013-07-17 | 2016-08-22 | 大塚製薬株式会社 | シアノトリアゾール化合物 |
US10626095B2 (en) | 2013-07-17 | 2020-04-21 | Otsuka Pharmaceutical Co., Ltd. | Cyanotriazole compounds |
JP2016135778A (ja) * | 2015-01-16 | 2016-07-28 | 大塚製薬株式会社 | シアノトリアゾール化合物の医薬用途 |
JP2019510787A (ja) * | 2016-04-05 | 2019-04-18 | イミューン センサー リミテッド ライアビリティ カンパニー | cGASアンタゴニスト化合物 |
JP7116422B2 (ja) | 2016-04-05 | 2022-08-10 | イミューン センサー リミテッド ライアビリティ カンパニー | cGASアンタゴニスト化合物 |
US11597707B2 (en) | 2016-04-05 | 2023-03-07 | Immunesensor Therapeutics, Inc. | CGAS antagonist compounds |
Also Published As
Publication number | Publication date |
---|---|
EP1605967A1 (de) | 2005-12-21 |
WO2004080481A1 (en) | 2004-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2007523842A (ja) | 酸安定化されたインスリンを含有する薬学的製剤 | |
US7879893B2 (en) | Ligands for the HisB10 Zn2 + sites of the R-state insulin hexamer | |
US20090123563A1 (en) | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | |
JP2008505866A (ja) | インスリンを含有する薬学的製剤 | |
JP2006519791A (ja) | 新規なnphインスリン製剤 | |
Langoth et al. | Thiolated chitosans: design and in vivo evaluation of a mucoadhesive buccal peptide drug delivery system | |
ES2297227T3 (es) | Composiciones farmaceuticas conteniendo insulina y ligandos del hexamero de insulina. | |
US20060069013A1 (en) | Pharmaceutical preparations comprising acid-stabilised insulin | |
JP2010504281A (ja) | アリールスルファニル化合物、および活性薬剤を送達するための組成物 | |
MXPA06013251A (es) | Compuestos y composiciones de aril-cetona para suministrar agentes activos. | |
US20050065066A1 (en) | Stabilised insulin compositions | |
US20060258561A1 (en) | Novel NPH insulin preparations | |
JP2006519791A5 (de) | ||
AU2002340773A1 (en) | Novel ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer | |
ZA200401839B (en) | Novel ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer. | |
KR20040044932A (ko) | R-상태 인슐린 헥사머의 HisB10 Zn2+ 부위에대한 신규한 리간드 | |
JPS5846026A (ja) | ヒトインシユリン,ヒトc−ペプタイドおよびヒトプロインシユリン含有製剤 | |
CN116635023A (zh) | 用于治疗糖尿病的离子液体制剂 | |
JP2002500187A (ja) | 多発性硬化症の治療方法 | |
JP2023539699A (ja) | 糖尿病を治療するためのイオン性液体製剤 | |
JPWO2020234782A5 (de) | ||
WO2002072099A1 (fr) | Agent therapeutique et / ou prophylactique pour la cardiopathie ischemique diabetique | |
JPS63132884A (ja) | 新規のチオナフテン−2−カルボン酸の水溶性塩 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070302 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070302 |
|
A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20080630 |